AT384035T - Ether compounds, compositions and their use - Google Patents

Ether compounds, compositions and their use

Info

Publication number
AT384035T
AT384035T AT00921608T AT00921608T AT384035T AT 384035 T AT384035 T AT 384035T AT 00921608 T AT00921608 T AT 00921608T AT 00921608 T AT00921608 T AT 00921608T AT 384035 T AT384035 T AT 384035T
Authority
AT
Austria
Prior art keywords
compositions
use
ether compounds
ether
compounds
Prior art date
Application number
AT00921608T
Other languages
German (de)
Inventor
Jean-Louis Dasseux
Carmen Oniciu
Original Assignee
Esperion Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority to US12732199P priority Critical
Application filed by Esperion Therapeutics Inc filed Critical Esperion Therapeutics Inc
Publication of AT384035T publication Critical patent/AT384035T/en

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D233/00Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
    • C07D233/54Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
    • C07D233/66Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D233/72Two oxygen atoms, e.g. hydantoin
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07CACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C311/00Amides of sulfonic acids, i.e. compounds having singly-bound oxygen atoms of sulfo groups replaced by nitrogen atoms, not being part of nitro or nitroso groups
    • C07C311/01Sulfonamides having sulfur atoms of sulfonamide groups bound to acyclic carbon atoms
    • C07C311/02Sulfonamides having sulfur atoms of sulfonamide groups bound to acyclic carbon atoms of an acyclic saturated carbon skeleton
    • C07C311/03Sulfonamides having sulfur atoms of sulfonamide groups bound to acyclic carbon atoms of an acyclic saturated carbon skeleton having the nitrogen atoms of the sulfonamide groups bound to hydrogen atoms or to acyclic carbon atoms
    • C07C311/04Sulfonamides having sulfur atoms of sulfonamide groups bound to acyclic carbon atoms of an acyclic saturated carbon skeleton having the nitrogen atoms of the sulfonamide groups bound to hydrogen atoms or to acyclic carbon atoms to acyclic carbon atoms of hydrocarbon radicals substituted by singly-bound oxygen atoms
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07CACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C43/00Ethers; Compounds having groups, groups or groups
    • C07C43/02Ethers
    • C07C43/03Ethers having all ether-oxygen atoms bound to acyclic carbon atoms
    • C07C43/04Saturated ethers
    • C07C43/13Saturated ethers containing hydroxy or O-metal groups
    • C07C43/132Saturated ethers containing hydroxy or O-metal groups both carbon chains being substituted by hydroxy or O-metal groups
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07CACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C59/00Compounds having carboxyl groups bound to acyclic carbon atoms and containing any of the groups OH, O—metal, —CHO, keto, ether, groups, groups, or groups
    • C07C59/125Saturated compounds having only one carboxyl group and containing ether groups, groups, groups, or groups
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07FACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00Compounds containing elements of Groups 5 or 15 of the Periodic System
    • C07F9/02Phosphorus compounds
    • C07F9/06Phosphorus compounds without P—C bonds
    • C07F9/08Esters of oxyacids of phosphorus
    • C07F9/09Esters of phosphoric acids
    • C07F9/091Esters of phosphoric acids with hydroxyalkyl compounds with further substituents on alkyl
    • YGENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10STECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S514/00Drug, bio-affecting and body treating compositions
    • Y10S514/866Diabetes
    • YGENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10STECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S514/00Drug, bio-affecting and body treating compositions
    • Y10S514/909Obesity
AT00921608T 1999-04-01 2000-03-31 Ether compounds, compositions and their use AT384035T (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
US12732199P true 1999-04-01 1999-04-01

Publications (1)

Publication Number Publication Date
AT384035T true AT384035T (en) 2008-02-15

Family

ID=22429489

Family Applications (1)

Application Number Title Priority Date Filing Date
AT00921608T AT384035T (en) 1999-04-01 2000-03-31 Ether compounds, compositions and their use

Country Status (13)

Country Link
US (10) US6506799B1 (en)
EP (1) EP1204626B1 (en)
JP (1) JP2002541129A (en)
CN (2) CN101165036A (en)
AT (1) AT384035T (en)
AU (1) AU779784B2 (en)
BR (1) BR0009520A (en)
CA (1) CA2369074C (en)
DE (1) DE60037818D1 (en)
HK (1) HK1047082A1 (en)
IL (2) IL145712D0 (en)
MX (1) MXPA01009893A (en)
WO (1) WO2000059855A1 (en)

Families Citing this family (88)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MXPA01009893A (en) * 1999-04-01 2003-07-28 Esperion Therapeutics Inc Ether compounds, compositions, and uses thereof.
US20030225123A1 (en) * 2001-03-22 2003-12-04 Auerbach Bruce Jeffrey Antihypertensive agents and use
US8568766B2 (en) 2000-08-24 2013-10-29 Gattadahalli M. Anantharamaiah Peptides and peptide mimetics to treat pathologies associated with eye disease
US20020127263A1 (en) * 2001-02-27 2002-09-12 Wenda Carlyle Peroxisome proliferator-acitvated receptor gamma ligand eluting medical device
US20040148013A1 (en) * 2002-04-18 2004-07-29 Epstein Stephen E Stent-based delivery statins to prevent restenosis
US20050003041A1 (en) * 2001-05-01 2005-01-06 Gerhard Kamil Application of fluid bed technology in brewing
CN1283313C (en) * 2001-09-28 2006-11-08 埃斯佩里安医疗公司 Use of alpha-helix apolipoprotein or HDL-related protein in preparing drugs for prevention and treatment of restenosis by local administration
US20030170223A1 (en) * 2002-02-01 2003-09-11 Board Of Trustees Of Michigan State University Pulmonary vasodilator surfactant compositions and method of use
JP4025102B2 (en) * 2002-03-18 2007-12-19 富士フイルム株式会社 The positive resist composition
US20040009216A1 (en) * 2002-04-05 2004-01-15 Rodrigueza Wendi V. Compositions and methods for dosing liposomes of certain sizes to treat or prevent disease
JP2005522509A (en) * 2002-04-10 2005-07-28 エスペリオン セラピューティクス,インコーポレイテッド Long chain derivatives functionalized as acyl coenzyme -a mimic, the compositions and method of use and related cholesterol management
GB0209539D0 (en) * 2002-04-26 2002-06-05 Avecia Ltd Monomer Polymer and process
US20040029941A1 (en) * 2002-05-06 2004-02-12 Jennings Julianne E. Zonisamide use in obesity and eating disorders
AU2003231788B2 (en) 2002-05-17 2008-09-11 Duke University Method for treating obesity
US20050215552A1 (en) * 2002-05-17 2005-09-29 Gadde Kishore M Method for treating obesity
BR0312426A (en) * 2002-07-03 2005-12-06 Esperion Therapeutics Inc Pharmaceutical composition, methods for treating, preventing or controlling a cholesterol, dyslipidemia or related disorders, to reduce or avoid adverse effects associated with a monotherapy pantethine and reducing or preventing an adverse effect associated with monotherapy second active agent and kit
US9655865B2 (en) 2002-07-29 2017-05-23 Veroscience, Llc Therapeutic treatment for metabolic syndrome, type 2 diabetes, obesity, or prediabetes
US20080200453A1 (en) 2002-07-29 2008-08-21 Cincotta Anthony H Methods of treating metabolic syndrome using dopamine receptor agonists
US20040220190A1 (en) * 2002-07-29 2004-11-04 Cincotta Anthony H. Methods of treating metabolic syndrome using dopamine receptor agonists
US20040081678A1 (en) * 2002-08-09 2004-04-29 Anthony Cincotta Therapeutic process for the treatment of obesity and associated metabolic disorders
US8821915B2 (en) 2002-08-09 2014-09-02 Veroscience, Llc Therapeutic process for the treatment of the metabolic syndrome and associated metabolic disorders
US20040048910A1 (en) * 2002-08-22 2004-03-11 Bove Susan Elizabeth Method of treating osteoarthritis
JP2006508973A (en) * 2002-11-15 2006-03-16 ワーナー−ランバート カンパニー リミティド ライアビリティー カンパニー Crp reduce the, and how to reduce systemic inflammation
DK2404890T3 (en) * 2003-01-23 2017-10-16 Esperion Therapeutics Inc Hydroxyl compounds and compositions for controlling cholesterol and related uses
DK2316456T3 (en) 2003-04-29 2017-09-11 Orexigen Therapeutics Inc Compositions for affecting weight loss comprising an opioid antagonist and bupropion
WO2005002557A1 (en) * 2003-07-03 2005-01-13 Warner-Lambert Company Llc Pharmaceutical compositions including an ether and selective cox-2 inhibitor and uses thereof
US20050074488A1 (en) * 2003-07-28 2005-04-07 Joel Melnick Use of vitamin Ds to down regulate the renin-angiotensin-aldosterone system
US20050148557A1 (en) * 2003-07-29 2005-07-07 Jin Tian Use of Vitamin Ds to treat kidney disease
US20060171983A1 (en) * 2003-07-30 2006-08-03 Jin Tian Use of Vitamin D receptor activators or Vitamin D analogs to treat cardiovascular disease
AT428411T (en) * 2003-11-07 2009-05-15 Jj Pharma Inc HDL-boosting combination therapy complexes
AU2003300438A1 (en) * 2003-12-24 2005-08-03 Esperion Therapeutics, Inc. Ether compounds and compositions for cholesterol management and related uses
KR20060128995A (en) 2004-01-13 2006-12-14 듀크 유니버시티 Compositions of an anticonvulsant and an antipsychotic drug for affecting weight loss
US7713959B2 (en) * 2004-01-13 2010-05-11 Duke University Compositions of an anticonvulsant and mirtazapine to prevent weight gain
US20060160750A1 (en) * 2004-01-13 2006-07-20 Krishnan K R R Compositions of an anticonvulsant and an antipsychotic drug and methods of using the same for affecting weight loss
EP1555021A1 (en) * 2004-01-16 2005-07-20 National Health Research Institutes Combinations of a mevalonate pathway inhibitor and a PPAR-gamma agonist for treating cancer
US20050215558A1 (en) * 2004-03-25 2005-09-29 Cincotta Anthony H Methods of identifying responders to dopamine agonist therapy
US8137993B2 (en) * 2004-03-25 2012-03-20 Veroscience Llc Methods of identifying responders to dopamine agonist therapy and treating metabolic conditions thereof
US8137994B2 (en) * 2004-03-25 2012-03-20 Veroscience Llc Methods of identifying responders to dopamine agonist therapy and treating metabolic conditions thereof
WO2005097206A2 (en) * 2004-04-06 2005-10-20 Cedars-Sinai Medical Center Prevention and treatment of vascular disease with recombinant adeno-associated virus vectors encoding apolipoprotein a-i and apolipoprotein a-i milano
WO2005107806A1 (en) * 2004-04-21 2005-11-17 Orexigen Therapeutics, Inc. Compositions for affecting weight loss
AU2005244151A1 (en) * 2004-05-03 2005-11-24 Duke University Compositions for affecting weight loss
KR20070029198A (en) * 2004-06-09 2007-03-13 아바니르 파마슈티컬스 Mediators of reverse cholesterol transport for the treatment of hypercholesterolemia
WO2005123700A1 (en) * 2004-06-09 2005-12-29 Avanir Pharmaceuticals Small molecules for treatment of hypercholesterolemia and related diseases
PE09862005A1 (en) * 2004-06-09 2006-02-03 Avanir Pharmaceuticals Heterocyclic derivatives mediators of reverse cholesterol transport
EA012440B1 (en) 2005-04-29 2009-10-30 Зе Риджентс Оф Зи Юнивесити Оф Кэлифонье The peptide-based compounds for the treatment of pathologies associated with inflammatory processes c
ES2402522T3 (en) 2005-11-22 2013-05-06 Orexigen Therapeutics, Inc. Compositions and procedures to increase insulin sensitivity
AR058239A1 (en) * 2005-11-28 2008-01-23 Orexigen Therapeutics Inc Methods for treating anxiety disorders
WO2007137400A1 (en) * 2006-06-01 2007-12-06 Institut De Cardiologie De Montreal Method and compound for the treatment of valvular stenosis
US8916195B2 (en) 2006-06-05 2014-12-23 Orexigen Therapeutics, Inc. Sustained release formulation of naltrexone
CA2659655A1 (en) 2006-08-08 2008-02-21 Alan M. Fogelman Salicylanilides enhance oral delivery of therapeutic peptides
US7777071B2 (en) 2006-08-11 2010-08-17 Ssv Therapeutics, Inc. Production of carnitine conjugate intermediates
ES2618500T3 (en) * 2006-10-20 2017-06-21 Neurendo Pharma, Llc Method to restore the incretin effect
EP2086924B1 (en) * 2006-11-01 2018-09-12 Piramal Imaging SA [f-18]-labeled l-glutamic acid, [f-18]-labeled l-glutamine, derivatives thereof and use thereof and processes for their preparation
CA2668885C (en) 2006-11-09 2016-08-02 Orexigen Therapeutics, Inc. Methods for administering weight loss medications
JP2010509367A (en) 2006-11-09 2010-03-25 オレキシジェン・セラピューティクス・インコーポレーテッド The layered pharmaceutical formulation
AT530178T (en) 2007-05-23 2011-11-15 Amcol International Corp With cholesterol interacting phyllosilicates and process for the reduction of hypercholesterolemia in a mammal
US20090004056A1 (en) * 2007-06-26 2009-01-01 Dade Behring Inc. Clinical Sample Analysis System Having An Analyzer Positioning Mechanism
EP2180787B1 (en) 2007-08-01 2013-10-30 University of Pittsburgh - Of the Commonwealth System of Higher Education Nitro oleic acid modulation of type ii diabetes
WO2009032702A2 (en) 2007-08-28 2009-03-12 Uab Research Foundation Synthetic apolipoprotein e mimicking polypeptides and methods of use
AU2008296478B9 (en) 2007-08-28 2015-03-19 The Uab Research Foundation Synthetic apolipoprotein E mimicking polypeptides and methods of use
US8101565B2 (en) * 2007-09-20 2012-01-24 Abbott Cardiovascular Systems Inc. Sustained release of Apo A-I mimetic peptides and methods of treatment
US7985727B1 (en) 2007-09-20 2011-07-26 Abbott Cardiovascular Systems Inc. Apo A-I mimetic peptides and methods of treatment
US7985728B1 (en) 2007-09-20 2011-07-26 Abbott Cardiovascular Systems Inc. Sustained release of Apo A-I mimetic peptides and methods of treatment
US9173890B2 (en) * 2007-09-20 2015-11-03 Abbott Cardiovascular Systems Inc. Sustained release of Apo A-I mimetic peptides and methods of treatment
US8044021B2 (en) * 2007-09-20 2011-10-25 Abbott Cardiovascular Systems Inc. Sustained release of apo A-I mimetic peptides and methods of treatment
DK2280928T3 (en) 2008-05-01 2018-11-05 Complexa Inc Vinyl-substituted fatty acids
JP2011521973A (en) * 2008-05-30 2011-07-28 オレキシジェン・セラピューティクス・インコーポレーテッド Methods for treating visceral fat conditions
WO2009155439A2 (en) 2008-06-19 2009-12-23 University Of Utah Research Foundation Use of nitrated lipids for treatment of side effects of toxic medical therapies
US20140024713A1 (en) 2008-06-19 2014-01-23 University Of Utah Research Foundation Use of nitrated lipids for treatment of side effects of toxic medical therapies
WO2010083611A1 (en) 2009-01-23 2010-07-29 Institut De Cardiologie De Montreal Method for the prevention and treatment of diastolic dysfunction employing an apolipoproteina1 (apoa1) mimetic peptide/phospholipid complex
SG173624A1 (en) 2009-02-16 2011-09-29 Cerenis Therapeutics Sa Apolipoprotein a-i mimics
US9352025B2 (en) 2009-06-05 2016-05-31 Veroscience Llc Combination of dopamine agonists plus first phase insulin secretagogues for the treatment of metabolic disorders
CA2769624C (en) 2009-07-31 2018-09-11 University Of Pittsburgh - Of The Commonwealth System Of Higher Education Electrophilic fatty acid derivatives as anti-inflammatory agents
ES2670576T3 (en) 2009-09-03 2018-05-31 Pfizer Vaccines Llc PCSK9 vaccine
US8686167B2 (en) * 2009-10-02 2014-04-01 Complexa, Inc. Heteroatom containing substituted fatty acids
RU2616496C2 (en) * 2010-01-11 2017-04-17 Ориксиджен Терапьютикс, Инк. Methods of weight loss therapy in patients with dominant depression (versions)
US20130137628A1 (en) 2010-05-11 2013-05-30 Esperion Therapeutics, Inc. Dimeric Oxidation-Resistant Apolipoprotein A1 Variants
ES2608177T3 (en) 2010-12-27 2017-04-06 Gemphire Therapeutics Inc. Gemcabeno and derivatives for the treatment of pancreatitis
AU2015202580B2 (en) * 2010-12-27 2016-06-16 Gemphire Therapeutics Inc. Gemcabene and derivatives for treating pancreatitis
US20140004142A1 (en) 2011-03-02 2014-01-02 Pfizer Inc. Pcsk9 vaccine
EP2744491A4 (en) 2011-08-19 2015-01-14 Univ Utah Res Found Combination therapy with nitrated lipids and inhibitors of the renin-angiotensin-aldosterone system
CA2875056A1 (en) 2012-06-06 2013-12-12 Orexigen Therapeutics, Inc. Methods of treating overweight and obesity
EP3104877A1 (en) 2014-02-11 2016-12-21 The USA, as represented by The Secretary, Department of Health and Human Services Pcsk9 vaccine and methods of using the same
RU2016144908A3 (en) 2014-05-02 2018-12-18
CN107405343A (en) 2014-11-07 2017-11-28 明尼苏达大学董事会 Salts and compositions useful for treating disease
WO2016077832A2 (en) 2014-11-14 2016-05-19 Gemphire Therapeutics Inc. PROCESSES AND INTERMEDIATES FOR PREPARING α,ω-DICARBOXYLIC ACID-TERMINATED DIALKANE ETHERS
US20170031954A1 (en) * 2015-07-27 2017-02-02 Alexandre PESTOV Image association content storage and retrieval system
CN105801405A (en) * 2016-05-23 2016-07-27 天津迪尔斯化学科技有限公司 Lipid-reducing small-molecular compound, intermediate and preparation methods of lipid-reducing small-molecular compound and intermediate

Family Cites Families (32)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3152148A (en) 1963-01-03 1964-10-06 Dow Chemical Co Preparation of comenic and pyromeconic acids
IL32518A (en) * 1968-07-29 1974-03-14 Upjohn Co Prostaglandins and analogs thereof
GB1269658A (en) 1968-07-29 1972-04-06 Upjohn Co Improvements in or relating to prostaglandins and the manufacture thereof
US3773946A (en) 1969-09-02 1973-11-20 Parke Davis & Co Triglyceride-lowering compositions and methods
US3930024A (en) 1969-09-02 1975-12-30 Parke Davis & Co Pharmaceutical compositions and methods
JPS6022708B2 (en) * 1977-07-14 1985-06-03 Ono Pharmaceutical Co
JPS6242903B2 (en) 1978-08-04 1987-09-10 Takeda Chemical Industries Ltd
JPS5736260B2 (en) 1979-09-04 1982-08-03
IL64542D0 (en) 1981-12-15 1982-03-31 Yissum Res Dev Co Long-chain alpha,omega-dicarboxylic acids and derivatives thereof and pharmaceutical compositions containing them
IT1164254B (en) 1983-05-30 1987-04-08 Luso Farmaco Inst 3- (3-idrossibutossi) -1-butanol and its method of preparation
JPH0455168B2 (en) 1983-12-26 1992-09-02 Eisai Co Ltd
DE3423166A1 (en) 1984-06-22 1986-01-02 Epis Sa Alpha, omega-dicarboxylic acids, process for their preparation and pharmaceutical compositions containing these compounds
US4714762A (en) 1986-10-31 1987-12-22 Warner-Lambert Company Antiarteriosclerotic substituted benzimidazol-2-yl-and 3H-imidazo[4,5-b]pyridin-2-yl-phenoxy-alkanoic acids and salts and esters thereof
CA1323364C (en) 1987-01-28 1993-10-19 Ryuzo Ueno Prostaglandins e and anti ulcer agents containing same
US5380709A (en) 1987-01-28 1995-01-10 K.K. Ueno Seiyaku Oyo Kenkyujo Prostaglandins E and anti ulcers containing same
US5166174A (en) 1987-01-28 1992-11-24 K.K. Ueno Seiyaku Oyo Kenkyujo Prostaglandins E and anti-ulcers containing same
US5225439A (en) 1987-01-28 1993-07-06 K.K. Ueno Seiyaku Oyo Kenkyujo Prostaglandins E and anti ulcers containing same
GB8717435D0 (en) 1987-07-23 1987-08-26 Easibind Ltd Fastening device
US5468755A (en) * 1988-05-10 1995-11-21 The Board Of Supervisors Of Louisiana State University And Agricultural And Mechanical College Therapeutic process for the treatment of the pathologies of Type II diabetes
JP2999579B2 (en) 1990-07-18 2000-01-17 武田薬品工業株式会社 Dna and its applications
DE4416447C1 (en) 1994-05-10 1995-08-24 Aqua Medic Anlagenbau Gmbh Protein foam removal from sea water aquarium
US5447922A (en) * 1994-08-24 1995-09-05 Bristol-Myers Squibb Company α-phosphonosulfinic squalene synthetase inhibitors
SE9500778D0 (en) 1995-03-03 1995-03-03 Pharmacia Ab Process for Producing a Protein
US5648387A (en) 1995-03-24 1997-07-15 Warner-Lambert Company Carboxyalkylethers, formulations, and treatment of vascular diseases
TW438587B (en) * 1995-06-20 2001-06-07 Takeda Chemical Industries Ltd A pharmaceutical composition for prophylaxis and treatment of diabetes
IL119971A (en) 1997-01-07 2003-02-12 Yissum Res Dev Co Pharmaceutical compositions containing dicarboxylic acids and derivatives thereof and some novel dicarboxylic acids
IL121165D0 (en) 1997-06-26 1997-11-20 Yissum Res Dev Co Pharmaceutical compositions containing carboxylic acids and derivatives thereof
US6037323A (en) 1997-09-29 2000-03-14 Jean-Louis Dasseux Apolipoprotein A-I agonists and their use to treat dyslipidemic disorders
US6004925A (en) 1997-09-29 1999-12-21 J. L. Dasseux Apolipoprotein A-I agonists and their use to treat dyslipidemic disorders
US6184422B1 (en) * 1998-02-26 2001-02-06 Hoffman-La Roche Inc. Cyclohexanediol derivatives
MXPA01009893A (en) * 1999-04-01 2003-07-28 Esperion Therapeutics Inc Ether compounds, compositions, and uses thereof.
BR0114619A (en) * 2000-10-11 2005-12-13 Esperion Therapeutics Inc The compound, pharmaceutical composition, methods for treating or preventing a cardiovascular disease, a dyslipidemia, a dyslipoproteinemia, a disorder of glucose metabolism, thrombosis and associated with the activated receptor peroxisome proliferator, Alzheimer's disease, Syndrome X or metabolic syndrome , septicemia, obesity, pancreatitis, hypertension, kidney disease, cancer, inflammation and impotence in a patient and to reduce the fat meat in animal breeding and of poultry eggs cholesterol

Also Published As

Publication number Publication date
EP1204626A4 (en) 2003-05-07
EP1204626A1 (en) 2002-05-15
AU779784B2 (en) 2005-02-10
BR0009520A (en) 2002-06-11
AU4190100A (en) 2000-10-23
US6831105B2 (en) 2004-12-14
US6459003B1 (en) 2002-10-01
US20030149094A1 (en) 2003-08-07
US20050119333A1 (en) 2005-06-02
US20100256209A1 (en) 2010-10-07
HK1047082A1 (en) 2008-06-06
US20040082548A1 (en) 2004-04-29
US6410802B1 (en) 2002-06-25
US6790953B2 (en) 2004-09-14
JP2002541129A (en) 2002-12-03
US20030125559A1 (en) 2003-07-03
US6909014B2 (en) 2005-06-21
MXPA01009893A (en) 2003-07-28
US20030065195A1 (en) 2003-04-03
DE60037818D1 (en) 2008-03-06
US20050004082A1 (en) 2005-01-06
US7192940B2 (en) 2007-03-20
IL145712D0 (en) 2002-07-25
CA2369074C (en) 2012-03-13
CA2369074A1 (en) 2000-10-12
CN1353684A (en) 2002-06-12
US7709515B2 (en) 2010-05-04
IL178952D0 (en) 2007-03-08
CN1329359C (en) 2007-08-01
WO2000059855A1 (en) 2000-10-12
US6646170B2 (en) 2003-11-11
EP1204626B1 (en) 2008-01-16
US6506799B1 (en) 2003-01-14
CN101165036A (en) 2008-04-23

Similar Documents

Publication Publication Date Title
DE50010295D1 (en) Intervertebral nucleus-prosthesis
DE60021496D1 (en) Secure wireless local area network
DE60024673D1 (en) Polypropylene composition
DE60236600D1 (en) Substituted 1h-dihydropyrazole, their production and use
NO20015607D0 (en) Glukagonantagonister / inversagonister
NO20014463L (en) Hydrofonmontasje
NO20013418D0 (en) Leketöybyggesett
DE60024854D1 (en) 4,5-di-substituted 2-aminopyrimidine
FI981011A0 (en) New compositions
NO20014317L (en) pyrimidine
DE69736642D1 (en) Heterocyclic compounds, their preparation and use
NO2009003I1 (en) etravirine
DE69840599D1 (en) Antimicrobial quinolones, their compositions and their uses
DK1233712T3 (en) intramedullary as
ID27415A (en) composition farmaseutik
DE60100550D1 (en) Oil-soluble molybdenum-containing compositions
NO20022481D0 (en) NPYY5 antagonists
NO20020214L (en) substituted oksoazaheterocyklylforbindelser
NO20033715D0 (en) new compositions
DE60141760D1 (en) Fad4, fad5, fad5-2, and fad6, members of fettsäuredesaturasefamilie and their uses
AT424815T (en) Stabilized reverse-micelle-compositions and their use
NO322703B1 (en) Glucopyranosyloxypyrazole, medicinal compositions containing the same and intermediates for the preparation thereof
DE60026966D1 (en) new use
NO20022947L (en) Substituted piperazine piperidinkalsiumkanal- blocking connections
NO20013691D0 (en) binder

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties